Publications by authors named "Wei Jia Fang"
Article Synopsis
- - The CAPability-01 trial studied the effectiveness of combining the PD-1 antibody sintilimab with the HDAC inhibitor chidamide, with or without the VEGF antibody bevacizumab, in patients who have advanced colorectal cancer resistant to chemotherapy.
- - Results showed that the combination therapy (triplet arm) significantly improved progression-free survival and overall response rates compared to the dual therapy (doublet arm), indicating increased treatment efficacy.
- - Patients experienced various adverse side effects, with two treatment-related deaths reported; however, the analysis suggested the triplet therapy led to enhanced immune activity in the tumor environment.
Article Synopsis
- - The study aimed to assess whether adding high-dose vitamin C to the standard chemotherapy (FOLFOX ± bevacizumab) would improve outcomes for patients with metastatic colorectal cancer (mCRC).
- - Results showed that there was no significant difference in progression-free survival (PFS), overall survival (OS), or response rates between the vitamin C group and the control group, although patients with RAS mutations did experience longer PFS with vitamin C.
- - Overall, high-dose vitamin C did not provide a clear benefit over standard chemotherapy for mCRC, except potentially for patients with specific genetic mutations (RAS mutation).
Article Synopsis
- - The phase III AXEPT study found that modified capecitabine plus irinotecan (mXELIRI), with or without bevacizumab, is as effective as the traditional treatment (FOLFIRI) for treating metastatic colorectal cancer in the second-line setting.
- - The study examined how the UGT1A1 genetic variations affect the treatment's effectiveness and safety, categorizing patients into groups based on their genotype.
- - Results showed that mXELIRI generally provides similar or better survival outcomes compared to FOLFIRI across different UGT1A1 genotypes, suggesting mXELIRI could become a standard treatment option regardless of genetic differences.
Antibiotics and immunotherapy in gastrointestinal tumors: Friend or foe?
World J Clin Cases
June 2019
The incidence of gastrointestinal (GI) tumors is increasing year by year, and its pathogenesis is closely related to the intestinal flora. At present, the use of antibiotics is very common in the clinic. And cancer patients with low immunity are vulnerable to all sorts of infections, such as respiratory tract infections and urinary tract infections.
View Article and Find Full Text PDFBackground: Serum soluble CD40 ligand (sCD40L) concentrations are increased in patients with nasopharyngeal carcinoma (NPC). This study further evaluated the relationship between plasma sCD40L concentrations and long-term survival of NPC.
Methods: Plasma sCD40L concentrations of 312 patients and 312 healthy controls were determined using an ELISA.
Background: Aberrant expression of HOX gene expression has been observed in cancer. The purpose of this study was to investigate the alteration of HOXA5 and HOXA9 expression and their clinical significance in acute meloid leukemia (AML).
Materials And Methods: The expression of HOXA5 and HOXA9 genes of bone marrow samples from 75 newly diagnosed AML patients and 22 healthy controls for comparison were examined by Real- time quantitative PCR (RQ-PCR) assay.
Background: Clostridium difficile carriage has been considered as a potential source for the deadly infection, but its role in cancer patients is still unclear. We aimed to identify the clinical and immunological factors that are related to C. difficile carriage in Chinese cancer patients.
View Article and Find Full Text PDFA DNA minor groove binder shows high effectiveness as a quencher for FRET probes.
Bioorg Med Chem Lett
August 2014
Article Synopsis
- A new non-fluorescent quencher using thiazole orange was added to oligonucleotides to enhance their performance in experiments.
- It was shown to effectively work with fluorescein amidite dyes in fluorimetry and real-time polymerase chain reaction (PCR) tests.
- The thiazole orange quencher improves the stability of DNA duplexes, which can help create shorter and more precise probes, and it was also effective in TaqMan probes.
Background: Colorectal cancer is one of the leading causes of mortality worldwide. Genome wide analysis studies have identified sequence mutations causing loss-of-function that are associated with disease occurrence and severity. Epigenetic modifications, such DNA methylation, have also been implicated in many cancers but have yet to be examined in the East Asian population of colorectal cancer patients.
View Article and Find Full Text PDFS-1 is an oral antitumor agent that contains tegafur, which is converted to fluorouracil (5-FU) in the human body. Cytochrome P450 2A6 (CYP2A6) is the principal enzyme responsible for bioconversion of tegafur to 5-FU. A number of CYP2A6 polymorphisms have been associated with variations in enzyme activity in several ethnic populations.
View Article and Find Full Text PDFBackground: The objective is to elucidate the effects of oral bifid triple viable probiotics among patients with colorectal cancer.
Methods: Sixty patients undergoing radical colorectal resection were randomly assigned to 3-day (days -5 to -3) preoperative probiotics (group A, n = 30) or placebo (group B, n = 30) treatment. The alteration of intestinal flora was evaluated by fecal cultures of Escherichia coli, Bifidobacterium longum and intestinal fungi; the gut barrier function by serum endotoxins and D-lactic acids and the immune and stress responses by peripheral blood immunoglobins, interleukin-6 and C-reactive protein.
A phase II clinical trial was performed to evaluate the efficacy and safety of gefitinib on pretreated Chinese female non-small-cell lung cancer (NSCLC) patients. Chinese female patients with locally advanced or metastatic NSCLC who failed at least one platinum-based chemotherapy received gefitinib monotherapy (250 mg/day) between April 2002 and January 2010. The primary endpoint was overall response rate (ORR), and secondary endpoints were overall survival (OS) and progression-free survival (PFS).
View Article and Find Full Text PDFClinical significance of K-ras and BRAF mutations in Chinese colorectal cancer patients.
World J Gastroenterol
February 2011
Article Synopsis
- - The study focused on identifying mutations in the K-ras and BRAF genes in 118 Chinese colorectal cancer patients to see how these mutations relate to clinical features and patient outcomes.
- - Results showed that 34.7% of patients had K-ras mutations, primarily at codons 12 and 13, with a significant association found between K-ras mutations and female gender; however, other clinical factors and patient survival were not linked to these mutations.
- - Only two patients had BRAF mutations, indicating that such mutations are rare in this population, while K-ras mutations appear common but do not serve as independent prognostic indicators for CRC.
Purpose: To evaluate the efficacy and safety of FOLFIRI regimen in patients with advanced colorectal cancer refractory to fluoropyrimidine and oxaliplatin.
Methods: The FOLFIRI regimen consisted of intravenous infusion of irinotecan 180 mg/m(2) on day 1 plus leucovorin (LV) 400 mg/m(2) on day 1 plus 5-fluorouracil (5-FU) 400 mg/m(2) bolus on day 1 plus 46-hour intravenous infusion of 5-FU 2,400 mg/m(2), every 2 weeks as one cycle. The main selection criterion for this study was the advanced colorectal cancer refractory to fluoropyrimidine and oxaliplatin.
Purpose: To evaluate the efficacy and toxicity of leucovorin (LV) plus 5-fluorouracil (5-FU) combined with oxaliplatin every 2 weeks on previously untreated advanced colorectal cancer patients in Chinese population.
Patients And Methods: Forty-nine patients were enrolled to receive, entirely as inpatients, 2-weekly cycles of oxaliplatin 85 mg/m2 i.v.
Background: Recent studies have demonstrated the effectiveness of cisplatin-based combinations in patients with advanced transitional cell carcinoma(TCC) of the urothelium. Concern over cisplatin toxicity instigated a search for alternative regimens. The aim of the study was to evaluate the activity and tolerability of gemcitabine plus carboplatin combination as first-line treatment in patients with advanced transitional cell carcinoma of the urothelium.
View Article and Find Full Text PDF